Mild to Moderate Hepatic Impairment Has No Effect on the Single Dose Pharmacokinetics of Alisporivir (ALV)

被引：0
|
作者：
Kovacs, Steven J.
Ke, June
Praestgaard, Jens
Barve, Avantika
Zhang, Jie
Maietta, Robert
Sunkara, Gangadhar
Stein, Daniel S.
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S977 / S977
页数：1
相关论文
共 50 条
  • [31] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
  • [32] FTY720 pharmacokinetics in mild to moderate hepatic impairment
    Kovarik, JM
    Schmouder, RL
    Wang, SY
    Wiegand, H
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04): : 446 - 452
  • [33] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    Critical Care, 12 (Suppl 2):
  • [34] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF TASOCITINIB (CP-690,550)
    Lawendy, N.
    Chan, G.
    Wang, R.
    Lamba, M.
    Krishnaswami, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S93 - S94
  • [35] Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment
    Grasela, DM
    Christofalo, B
    Kollia, GD
    Duncan, G
    Noveck, R
    Manning, JA
    LaCreta, FP
    PHARMACOTHERAPY, 2000, 20 (06): : 87S - 94S
  • [36] Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen
    Yan, Jing-He
    Taylor, Amanda
    Clough, Timothy
    Burmeister-Getz, Elise
    Pazdirkova, Marketa
    Russo, Cesare
    CIRCULATION, 2024, 150
  • [37] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [38] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1368 - 1374
  • [39] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
  • [40] Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.
    Akce, Mehmet
    El-Khoueiry, Anthony B.
    Piha-Paul, Sarina Anne
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Milton, Ashley
    Judson, Patricia
    O'Bryant, Cindy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345